阿坎酸治疗酒依赖的疗效与安全性分析

发布时间：2018-01-16 18:09

本文关键词：阿坎酸治疗酒依赖的疗效与安全性分析　出处：《暨南大学》2015年硕士论文　论文类型：学位论文

【摘要】：目的:评价阿坎酸治疗酒依赖的疗效及安全性。方法:检索Pubmed、Web of Science、EMbase、The Cochrane Central Register of Controlled Trials、The Cochrane Library、中国科技期刊数据库(维普)、相关期刊论文(CNKI)、万方全文数据库等关于阿坎酸治疗酒依赖的临床随机对照研究,采用Rev Man 5.2.0软件对入选研究进行Meta分析。结果:共纳入27个随机对照试验(RCT),包含6839例酒依赖患者。Meta分析结果显示:①与安慰剂比较,阿坎酸可以减少12%的患者再度饮酒(RR:0.88,95%CI:0.83~0.93,P0.00001),并延长累计戒酒时间(MD:10.66,95%CI:4.93~16.39,P=0.0003);根据治疗时间分(2-4)月、6月、12月三个亚组,结果提示随治疗时间延长阿坎酸的治疗效益增大(RR:0.90,RR:0.86,RR:0.86;MD=8.40,MD=8.94,MD=12.24);②在再度重度饮酒率及GGT水平方面,阿坎酸与安慰剂比较无明显统计学差异(RR:0.98,95%CI:0.93~1.04,P=0.52;MD:-10.7,95%CI:-22.3~0.89,P=0.07);根据治疗时间进行亚组分析,结果仍无统计学差异;③在不良反应方面,阿坎酸组仅腹泻发生率高于安慰剂组(P0.00001),而腹痛、便秘、恶心、呕吐、瘙痒、头痛、失眠发生率阿坎酸组与安慰剂组之间无明显统计学差异。结论:阿坎酸可以降低酒依赖患者的再度饮酒率,延长累计戒酒时间,且随治疗时间的延长治疗效益增大,但不能降低再度重度饮酒率,不良反应少,可以作为酒依赖患者的治疗药物。
[Abstract]:Objective: to evaluate the efficacy and safety of arcanic acid in the treatment of alcohol dependence. The Cochrane Central Register of Controlled Trials. The Cochrane Library, China Science and Technology Journal Database. Wanfang Full-text Database and other clinical randomized controlled studies on the treatment of alcohol dependence with acanolic acid. Rev Man 5.2.0 software was used to analyze the Meta of the selected study. Results: a total of 27 randomized controlled trials were conducted. A meta-analysis of 6839 patients with alcohol dependence showed that Acanic acid could reduce the amount of alcohol consumed by 12% patients by 12% compared with placebo by RR: 0.88. 95 CI: 0.83 + 0.93% P0.00001, and the cumulative abstinence time should be increased to 10. 66% and 95% CI: 4.93% 16.39. P0. 0003; According to the treatment time divided into 2-4) months, June, December, three subgroups, the results showed that with the prolongation of the treatment time, the therapeutic benefits of arcanic acid increased with the increase of RR: 0.90% RR: 0.86. RR: 0.86; MDS 8.40, MDN 8.94, MDN 12.24; (2) there was no significant difference in the rate of heavy drinking and the level of GGT between arcanic acid and placebo. There was no significant difference in RR: 0.98 and 95% CI: 0.931.04% P0.52; MD: -10.7 and 95CI: -22.30.89% P0.07; The results of subgroup analysis were not statistically different according to the time of treatment. 3The incidence of diarrhea in acanic acid group was higher than that in placebo group (P 0.00001), but abdominal pain, constipation, nausea, vomiting, itching and headache. There was no significant difference in the incidence of insomnia between the arcanic acid group and the placebo group. Conclusion: arcanic acid can reduce the alcohol consumption rate in patients with alcohol dependence and prolong the cumulative abstinence time. With the prolongation of treatment time, the benefit of treatment increases, but it can not reduce the rate of heavy drinking again, and the adverse reaction is less, so it can be used as a therapeutic drug for patients with alcohol dependence.
【学位授予单位】：暨南大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：R749.62

【相似文献】